Adverum Biotechnologies, Inc. (ADVM) Financial Ratios
13 years of historical data (2012–2024) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
1.22
↓-84% vs avg
5yr avg: 7.68
30Y Low1.3·High82.2
ROE
↓
-189.8%
↑-122% vs avg
5yr avg: -85.5%
30Y Low-190%·High-24%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
ADVM Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Adverum Biotechnologies, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $96M | $92M | $437M | $336M | $1.7B | $10.1B | $8.5B | $1.9B | $1.5B | $1.1B | $2.5B |
| Enterprise Value | $127M | $123M | $436M | $375M | $1.8B | $10.1B | $8.5B | $1.8B | $1.5B | $829M | $2.2B |
| P/E Ratio → | -0.66 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 96.26 | 92.38 | 121.27 | — | 230.82 | — | 34005.66 | 1199.33 | 826.47 | 722.43 | 1061.56 |
| P/B Ratio | 1.22 | 1.31 | 6.49 | 1.85 | 5.48 | 23.29 | 48.59 | 9.61 | 8.30 | 4.88 | 9.75 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
ADVM EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 123.43 | 121.00 | — | 239.99 | — | 33871.86 | 1103.39 | 788.54 | 569.73 | 949.84 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
ADVM Profitability
Margins and return-on-capital ratios measuring operating efficiency
Adverum Biotechnologies, Inc. earns an operating margin of -13915.9%. Operating margins have compressed from -3581.7% to -13915.9% over the past 3 years, signaling potential cost pressures or competitive headwinds. A negative ROE of -189.8% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | 100.0% | 100.0% | — | 100.0% | — | — | — | — | — | 100.0% |
| Operating Margin | -13915.9% | -13915.9% | -3581.7% | — | -1948.3% | — | -27418.0% | -4843.7% | -3182.6% | -7923.3% | -2062.2% |
| Net Profit Margin | -13092.7% | -13092.7% | -3392.1% | — | -1940.5% | — | -25794.4% | -4505.4% | -3036.6% | -7817.7% | -2046.3% |
Return on Capital
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -189.8% | -189.8% | -98.2% | -62.1% | -38.8% | -38.6% | -34.3% | -37.7% | -28.1% | -48.6% | -23.6% |
| ROA | -78.0% | -78.0% | -52.6% | -41.3% | -31.6% | -33.3% | -29.6% | -35.0% | -25.7% | -45.6% | -22.3% |
| ROIC | -124.2% | -124.2% | -67.6% | -39.0% | -27.8% | -32.5% | -54.7% | -73.0% | -82.2% | — | — |
| ROCE | -95.1% | -95.1% | -62.6% | -45.2% | -33.2% | -35.5% | -33.8% | -39.6% | -28.3% | -47.8% | -23.1% |
ADVM Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Net debt stands at $31M ($92M total debt minus $61M cash).
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 1.30 | 1.30 | 1.10 | 0.59 | 0.33 | 0.07 | 0.19 | 0.00 | 0.00 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | 0.44 | -0.01 | 0.21 | 0.22 | -0.07 | -0.19 | -0.77 | -0.38 | -1.03 | -1.03 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — |
ADVM Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Adverum Biotechnologies, Inc.'s current ratio of 5.73x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 5.91x to 5.73x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 5.73 | 5.73 | 5.14 | 5.91 | 14.88 | 20.82 | 9.06 | 19.48 | 18.15 | 22.76 | 39.70 |
| Quick Ratio | 5.73 | 5.73 | 5.14 | 5.91 | 14.88 | 20.82 | 9.06 | 19.48 | 18.15 | 22.76 | 39.70 |
| Cash Ratio | 5.49 | 5.49 | 4.83 | 5.76 | 14.31 | 20.59 | 8.55 | 19.13 | 17.85 | 22.45 | 39.41 |
| Asset Turnover | — | 0.01 | 0.02 | — | 0.02 | — | 0.00 | 0.01 | 0.01 | 0.01 | 0.01 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | 277.84 | — | — | — | — | 222.26 | 70.67 |
ADVM Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Adverum Biotechnologies, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $20M | $58M | $58M | $98M | $93M | $74M | $61M | $44M | $36M | $26M |
Peer Comparison
Compare ADVM with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 ADVMYou | $96M | -0.7 | — | — | 100.0% | -13915.9% | -189.8% | -124.2% | — |
 OCGN | $420M | -5.4 | — | — | 45.9% | -1425.7% | -776.9% | -1565.6% | — |
 EDIT | $263M | -1.5 | — | — | 100.0% | -245.2% | -198.1% | — | — |
 KRYS | $10B | 50.9 | 58.2 | 54.3 | 92.6% | 41.5% | 18.9% | 18.0% | 0.1 |
 RARE | $3B | -4.7 | — | — | 83.8% | -79.5% | -607.5% | -89.4% | — |
 BMRN | $11B | 30.4 | 16.1 | 14.5 | 77.1% | 16.6% | 5.9% | 7.4% | 1.0 |
 SRPT | $2B | -2.5 | — | — | 59.9% | -29.9% | -53.5% | -31.4% | — |
 FOLD | $5B | -164.8 | 114.9 | 152.4 | 87.3% | 5.4% | -11.6% | 5.3% | 11.5 |
 RCKT | $366M | -1.7 | — | — | — | — | -60.3% | -62.4% | — |
 REGN | $63B | 14.7 | 15.3 | 15.5 | 85.4% | 24.9% | 14.9% | 8.9% | 0.7 |
 IONS | $12B | -31.1 | — | — | 98.3% | -40.5% | -70.7% | -12.8% | — |
| Healthcare Median | — | 22.1 | 14.2 | 18.5 | 63.9% | -4.3% | -32.6% | -11.6% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 13 years · Updated daily
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
ADVM — Frequently Asked Questions
Quick answers to the most common questions about buying ADVM stock.
What is Adverum Biotechnologies, Inc.'s P/E ratio?
Adverum Biotechnologies, Inc.'s current P/E ratio is -0.7x. This places it at the 50th percentile of its historical range.
What is Adverum Biotechnologies, Inc.'s ROE?
Adverum Biotechnologies, Inc.'s return on equity (ROE) is -189.8%. The historical average is -57.6%.
Is ADVM stock overvalued?
Based on historical data, Adverum Biotechnologies, Inc. is trading at a P/E of -0.7x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Adverum Biotechnologies, Inc.'s profit margins?
Adverum Biotechnologies, Inc. has 100.0% gross margin and -13915.9% operating margin.